Key result
5-fluorouracil acts as both an inhibitor and a mutagen during foot-and-mouth disease virus replication, making it an adequate drug for lethal mutagenesis.
5-fluorouracil demonstrates dual activity as an inhibitor and mutagen against foot-and-mouth disease virus, highlighting its potential in antiviral lethal mutagenesis strategies.
Supports 5-FU testing in FMDV; leaves open clinical translation pending in vivo trials.
5-fluorouracil (FU) is a pyrimidine analogue extensively used in cancer chemotherapy. FU can be metabolized into 5-fluorouridine-triphosphate, which can be used as substrate for viral RNA-dependent RNA polymerases. This results in the incorporation of mutations into viral RNA. Accumulation of mutations may lead to loss of virus infectivity, in a process known as lethal mutagenesis. RNA virus pathogens are particularly difficult to control because they are highly mutable, and mutants resistant to antiviral agents are readily selected. Here, we review the basic principles of lethal mutagenesis as an antiviral approach, and the participation of FU in its development. Recent studies with foot-and-mouth disease virus indicate that FU can act both as an inhibitor and as a mutagen during foot-and-mouth disease virus replication. This dual activity renders FU an adequate drug for lethal mutagenesis. We suggest that structural and biochemical studies can contribute to the lead to new design of base or nucleoside analogues targeted specifically to viral polymerases.
No takes yet. Share an insight, caveat, or question.
Agudo et al. (2009) conducted a review in Foot-and-mouth disease virus infection. 5-fluorouracil was evaluated. 5-fluorouracil acts as both an inhibitor and a mutagen during foot-and-mouth disease virus replication, making it an adequate drug for lethal mutagenesis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: